<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04186845</url>
  </required_header>
  <id_info>
    <org_study_id>BED-PSMA-302</org_study_id>
    <nct_id>NCT04186845</nct_id>
  </id_info>
  <brief_title>Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)</brief_title>
  <official_title>A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Men With Suspected Prostate Cancer Recurrence Based on Elevated PSA Following Prior Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blue Earth Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Blue Earth Diagnostics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and
      diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men
      with suspected prostate cancer recurrence based on elevated Prostate-specific antigen (PSA)
      following prior therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Positron Emission Tomography (PET) Imaging study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive Predictive Value (PPV) of rhPSMA-7.3 (18F) PET on a patient level using histopathology or confirmatory imaging as a Standard of Truth (SoT).</measure>
    <time_frame>90 days</time_frame>
    <description>PPV (defined as true positive [TP]/{TP+false positive [FP]}) of rhPSMA-7.3 (18F) PET using histopathology or confirmatory imaging as a Standard of Truth (SoT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inter-reader agreement of rhPSMA-7.3 (18F) scan interpretation by blinded independent readers.</measure>
    <time_frame>90 days</time_frame>
    <description>Kappa statistic for the agreement between blinded independent readers on the interpretation of rhPSMA-7.3 (18F) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-reader agreement of rhPSMA-7.3 (18F) scan interpretation by blinded independent readers.</measure>
    <time_frame>90 days</time_frame>
    <description>Kappa statistic for the agreement within blinded independent readers on the interpretation of rhPSMA-7.3 (18F) scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as classified by MedDRA</measure>
    <time_frame>90 days</time_frame>
    <description>Safety will be assessed from data on the occurrence of one or more treatment-emergent Adverse Events from the time of intravenous administration of 18F-rhPSMA-7.3 throughout the study period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhPSMA-7.3 (18F) Injection</intervention_name>
    <description>Radioligand for PET CT scanning</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is male and aged &gt;18 years old.

          2. History of localized adenocarcinoma of the prostate with prior curative intent
             treatment.

          3. An elevated PSA, clinically suspicious for biochemically recurrent disease:

               -  Following Radical Prostatectomy: PSA &gt;0.2 ng/mL

               -  Following Radiotherapy: nadir +2 ng/mL.

          4. Potentially eligible for salvage therapy with curative intent.

        Exclusion Criteria:

          1. Patients who are planned to have an x-ray contrast agent or other PET radiotracer &lt;24
             hours prior to the PET scan.

          2. Patients currently receiving Androgen Deprivation Therapy (ADT).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patients required to have suspected prostate cancer recurrence based on elevated PSA following prior therapy.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthew Cooney</last_name>
    <phone>+1 216 374 8221</phone>
    <email>matthew.cooney@parexel.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesco Paronelli</last_name>
    <phone>+39 0332 732603</phone>
    <email>Francesco.Paronelli@parexel.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tower Urology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Josephson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Przemyslaw Twardowski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Schuster</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northside Radiology Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Lavely</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian Chapin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Saltzstein</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates PC</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Fleming</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>FI-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Bostr√∂m</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent Prostate Cancer</keyword>
  <keyword>Diagnostic</keyword>
  <keyword>Prostate Specific Membrane Antigen (PSMA)</keyword>
  <keyword>Positron Emission Tomography (PET) Scan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

